Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

AGC Plans to Invest Over 200B Yen in CDMO Operations for Gene & Cell Therapy, More

Filed Under: Pharma Tagged With: , , , , ,

AGC Inc. (TYO:5201) is looking to invest more than 200 billion yen ($1.7 billion) into CDMO operations by 2025. Plans…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

AGC Looks to Advance Into Gene and Cell Therapy Business With Tender Offer for MolMed
AGC Looks to Advance Into Gene and Cell Therapy Business…
AGC in Race to Bolster CDMO Operations Across US, Europe and Japan
AGC in Race to Bolster CDMO Operations Across US, Europe and…
Japanese Chemical Companies Find Special Demand for Bio-CDMO Operations Amid COVID-19
Japanese Chemical Companies Find Special Demand for Bio-CDMO…
AGC Aims for Three Strategic Businesses to Make up 40% of Operating Profit in 2025
AGC Aims for Three Strategic Businesses to Make up 40% of…
JSR Eyes Operational Setup With Greater Resilience to Shifts in Business Climate
JSR Eyes Operational Setup With Greater Resilience to Shifts…
Sekisui Chemical to Build New Biopharmaceutical Plant in UK
Sekisui Chemical to Build New Biopharmaceutical Plant in UK